Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial.
primary studies published RCT
Details- 2021
- Griese M
Reflex zone stimulation reduces ventilation inhomogeneity in cystic fibrosis: A randomised controlled cross-over study.
primary studies published RCT
Details- 2021
- Jana P
Withdrawal of dornase alfa increases ventilation inhomogeneity in children with cystic fibrosis.
primary studies published RCT
Details- 2021
- Voldby C
How Many Maneuvers Should We Do for Maximal Inspiratory and Expiratory Muscle Pressure Testing in Children: A Retrospective Review in Children with Cystic Fibrosis.
primary studies published RCT
Details- 2021
- Boonjindasup W
Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis.
primary studies published RCT
Details- 2021
- Elborn JS
Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations.
primary studies published RCT
Details- 2020
- Munck A
Ivacaftor in cystic fibrosis with residual function: Lung function results from an N-of-1 study.
primary studies published RCT
Details- 2020
- Nick JA
The benefits of mechanical insufflator-exsufflator compared to autogenic drainage in adults with cystic fibrosis.
primary studies published RCT
Details- 2020
- Helper N
Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial.
primary studies published RCT
Details- 2020
- Devereux G
A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation.
primary studies published RCT
Details- 2020
- McKone EF